Medivir Abandons Separate Listing, Sells Off Commercial Unit

Medivir has decided a sale of its commercial arm BioPhausia makes better business sense than a separate listing, and is selling the unit to Karo Pharma for just over $100m.

Amid tough market conditions, Medivir AB CEO Niklas Prager is "convinced" that a sale of its Nordic Brands portfolio – operating as BioPhausia AB – to Karo Pharma "is the best way to maximize the value for our shareholders." He had been considering a separate listing on First North Premium, NASDAQ's European market for smaller, growing companies. (Also see "Medivir Plans For A Post-Simeprevir Future" - Scrip, 31 August, 2016.)

The SEK908m ($101m) cash and debt free sale to Karo Pharma means the commercial unit "can continue its positive development...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip